- call +1-201-465-4211
- email sales@mrinsights.biz
The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast period. Based on the drug class the market can be segmented into Beta blockers, ARBs, and ACE inhibitors. Angiotensin II receptor blockers (ARB) are a group of pharmaceuticals that modify the renin-angiotensin system. The heart disease drugs market is experiencing growth in the ARBs segment because it reduces the risk of death caused by heart failure and minimizes the chance of hospitalization of people with heart failure.
Scope of the Report:
This report focuses on the Heart Failure Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The latest trend gaining momentum in the market is investment inclination toward developing countries. Countries such as India, China, and Brazil are turning out to be some of the most attractive countries for pharmaceutical companies across the globe. Many factors such as huge share of global population and rising geriatric population are leading to the high growth of healthcare sector in the developing countries. In addition, the rising cases of lifestyle disorders such as obesity and diabetes also contribute to higher heart failure cases in the region.
One of the major drivers for this market is rising geriatric population. A large number of health problems are associated with the rising age, and CVDs are major among them. As a person gets older, the blood vessels become less flexible, thus making it difficult for the blood to flow through them. Rising age accompanied by other factors such as lifestyle-oriented diseases and smoking increases the risk of CVDs, especially heart failure. Heart failure in the geriatric population will continue to be a rising health burden globally, as this population represents the majority of the heart failure patients. Hence, rising geriatric population drives the demand for heart failure drugs during the forecast period.
The worldwide market for Heart Failure Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Amgen
AstraZeneca
Bayer
Novartis
Gilead
GlaxoSmithKline
Pfizer
Teva Pharmaceutical industries
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Beta Blockers
ARBs
ACE Inhibitors
Market Segment by Applications, can be divided into
Hospital
Pharmacy
Others
There are 15 Chapters to deeply display the global Heart Failure Drugs market.
Chapter 1, to describe Heart Failure Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Heart Failure Drugs, with sales, revenue, and price of Heart Failure Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Heart Failure Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Heart Failure Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Heart Failure Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Heart Failure Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Beta Blockers
1.2.2 ARBs
1.2.3 ACE Inhibitors
1.3 Market Analysis by Applications
1.3.1 Hospital
1.3.2 Pharmacy
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Heart Failure Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 AstraZeneca
2.2.1 Business Overview
2.2.2 Heart Failure Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 AstraZeneca Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bayer
2.3.1 Business Overview
2.3.2 Heart Failure Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bayer Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Novartis
2.4.1 Business Overview
2.4.2 Heart Failure Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Novartis Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Gilead
2.5.1 Business Overview
2.5.2 Heart Failure Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Gilead Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 GlaxoSmithKline
2.6.1 Business Overview
2.6.2 Heart Failure Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 GlaxoSmithKline Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Pfizer
2.7.1 Business Overview
2.7.2 Heart Failure Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Pfizer Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Teva Pharmaceutical industries
2.8.1 Business Overview
2.8.2 Heart Failure Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Teva Pharmaceutical industries Heart Failure Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Heart Failure Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Heart Failure Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Heart Failure Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Heart Failure Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Heart Failure Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Heart Failure Drugs Market Analysis by Regions
4.1 Global Heart Failure Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Heart Failure Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Heart Failure Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Heart Failure Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Heart Failure Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Heart Failure Drugs Sales and Growth Rate (2013-2018)
4.5 South America Heart Failure Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Heart Failure Drugs Sales and Growth Rate (2013-2018)
5 North America Heart Failure Drugs by Countries
5.1 North America Heart Failure Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Heart Failure Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Heart Failure Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Heart Failure Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Heart Failure Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Heart Failure Drugs Sales and Growth Rate (2013-2018)
6 Europe Heart Failure Drugs by Countries
6.1 Europe Heart Failure Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Heart Failure Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Heart Failure Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Heart Failure Drugs Sales and Growth Rate (2013-2018)
6.3 UK Heart Failure Drugs Sales and Growth Rate (2013-2018)
6.4 France Heart Failure Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Heart Failure Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Heart Failure Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Heart Failure Drugs by Countries
7.1 Asia-Pacific Heart Failure Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Heart Failure Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Heart Failure Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Heart Failure Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Heart Failure Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Heart Failure Drugs Sales and Growth Rate (2013-2018)
7.5 India Heart Failure Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Heart Failure Drugs Sales and Growth Rate (2013-2018)
8 South America Heart Failure Drugs by Countries
8.1 South America Heart Failure Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Heart Failure Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Heart Failure Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Heart Failure Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Heart Failure Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Heart Failure Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Heart Failure Drugs by Countries
9.1 Middle East and Africa Heart Failure Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Heart Failure Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Heart Failure Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Heart Failure Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Heart Failure Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Heart Failure Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Heart Failure Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Heart Failure Drugs Sales and Growth Rate (2013-2018)
10 Global Heart Failure Drugs Market Segment by Type
10.1 Global Heart Failure Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Heart Failure Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Heart Failure Drugs Revenue and Market Share by Type (2013-2018)
10.2 Beta Blockers Sales Growth and Price
10.2.1 Global Beta Blockers Sales Growth (2013-2018)
10.2.2 Global Beta Blockers Price (2013-2018)
10.3 ARBs Sales Growth and Price
10.3.1 Global ARBs Sales Growth (2013-2018)
10.3.2 Global ARBs Price (2013-2018)
10.4 ACE Inhibitors Sales Growth and Price
10.4.1 Global ACE Inhibitors Sales Growth (2013-2018)
10.4.2 Global ACE Inhibitors Price (2013-2018)
11 Global Heart Failure Drugs Market Segment by Application
11.1 Global Heart Failure Drugs Sales Market Share by Application (2013-2018)
11.2 Hospital Sales Growth (2013-2018)
11.3 Pharmacy Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Heart Failure Drugs Market Forecast (2018-2023)
12.1 Global Heart Failure Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Heart Failure Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Heart Failure Drugs Market Forecast (2018-2023)
12.2.2 Europe Heart Failure Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Heart Failure Drugs Market Forecast (2018-2023)
12.2.4 South America Heart Failure Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Heart Failure Drugs Market Forecast (2018-2023)
12.3 Heart Failure Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Heart Failure Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Heart Failure Drugs Market Share Forecast by Type (2018-2023)
12.4 Heart Failure Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Heart Failure Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Heart Failure Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Heart Failure Drugs Picture
Table Product Specifications of Heart Failure Drugs
Figure Global Sales Market Share of Heart Failure Drugs by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
